Skip to main content
. 2023 Nov 2;7(6):975–985. doi: 10.1007/s41669-023-00438-7

Fig. 2.

Fig. 2

Deterministic sensitivity analysis results for the cost effectiveness of RZV versus no vaccine strategy for US HSCT adults aged 35 years. Individual variation of an input that is also varied in this deterministic sensitivity analysis grouped with other potentially correlated inputs. HSCT hematopoietic stem cell transplant, HZ herpes zoster, ICER incremental cost-effectiveness ratio, PHN postherpetic neuralgia, QALY quality-adjusted life-year, RZV recombinant zoster vaccine, US United States, YOA years of age